Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis.

This letter discusses the case of a 58-year-old woman with relapsing remitting multiple sclerosis (RRMS) who experienced a severe exacerbation of psoriasis after being treated with ofatumumab, an anti-CD20 monoclonal antibody. Despite discontinuing ofatumumab and trying various treatments, her psoriasis continued to worsen. Eventually, she was treated with secukinumab, a fully human monoclonal IL-17A antibody approved for psoriasis, which resulted in significant improvement. The letter highlights the potential risk of worsening psoriasis with B-cell-depleting therapies in RRMS patients and suggests that anti-IL17 antibodies may be a good alternative treatment option. [Extracted from the article]